Role of Endogenous Endothelin in Chronic Heart Failure: Effect of Long-term Treatment With an Endothelin Antagonist on Survival, Hemodynamics, and Cardiac Remodeling
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Plasma levels of the vasoconstrictor peptide endothelin (ET) are increased in chronic heart failure (CHF), and ET levels are a major predictor of mortality in this disease. Thus, ET may play a deleterious role in CHF. The purpose of this study was to assess the effects of chronic treatment with the ET receptor antagonist bosentan in a rat model of CHF. Methods and Results Rats were subjected to coronary artery ligation and were treated for 2 or 9 months with placebo or bosentan (30 or 100 mg · kg−1· d−1). Bosentan 100 mg · kg−1 markedly increased survival (after 9 months: untreated, 47%; bosentan, 65%;P<.01). Throughout the 9-month treatment period, bosentan significantly reduced arterial pressure and heart rate. After 2 or 9 months of treatment, the ET antagonist reduced central venous pressure and left ventricular (LV) end-diastolic pressure as well as plasma catecholamines, urinary cGMP, and LV ventricular collagen density. Bosentan also reduced LV dilatation (evidenced at 2 months by a shift in the pressure/volume relationship ex vivo). Echocardiographic studies performed after 2 months showed that the ET antagonist reduced hypertrophy and increased contractility of the noninfarcted LV wall. The lower dose of bosentan (30 mg · kg−1), which had no major hemodynamic or structural effects, also had no effect on survival. Conclusions Long-term treatment with an ET antagonist markedly increases survival in this rat model of CHF. This increase in survival is associated with decreases in both preload and afterload and an increase in cardiac output as well as decreased LV hypertrophy, LV dilatation, and cardiac fibrosis. Thus, chronic treatment with ET antagonists such as bosentan might be beneficial in human CHF and might increase long-term survival in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Sahn, D. J., DeMaria, A., Kisslo, J., & Weyman, A. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430
Chi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure
Mantel, N. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500879 · Cited by 2,897
Myocardial infarct size and ventricular function in rats.
Pfeffer, M. A., Pfeffer, J. M., Fishbein, M. C., Fletcher, P. J., Spadaro, J., Kloner, R. A., & Braunwald, E. (1979) · Circulation Research · doi:10.1161/01.res.44.4.503 · Cited by 1,281
Pfeffer, M. A., Pfeffer, J. M., Steinberg, C., & Finn, P. (1985) · Circulation · doi:10.1161/01.cir.72.2.406 · Cited by 718
Clozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Clearance of Circulating Endothelin-1 by ETB Receptors in Rats
Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., & Nishikibe, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1395 · Cited by 625
Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., & Sugishita, Y. (1996) · Nature · doi:10.1038/384353a0 · Cited by 622
Endothelin in human congestive heart failure.
Wei, C. M., Lerman, A., Rodeheffer, R. J., McGregor, C. G., Brandt, R. R., Wright, S., Heublein, D. M., Kao, P. C., Edwards, W. D., & Burnett, J. C. (1994) · Circulation · doi:10.1161/01.cir.89.4.1580 · Cited by 586
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
Kiowski, W., Kim, J., Oechslin, E., Sütsch, G., Hunziker, P., Müller, P., Bertel, O., Schmitt, R., & Jones, R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91504-4 · Cited by 571
Cited by
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Haddad, F., Hunt, S. A., Rosenthal, D. N., & Murphy, D. J. (2008) · Circulation · doi:10.1161/circulationaha.107.653576 · Cited by 1,523
Haddad, F., Doyle, R., Murphy, D. J., & Hunt, S. A. (2008) · Circulation · doi:10.1161/circulationaha.107.653584 · Cited by 1,304
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
“In experimental animal models of hypertensive heart disease and of reparative myocardial fibrosis, ET-1 inhibition reduced fibrotic remodelling.(280,281)”
BackgroundCardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
Endothelin System: The Double-Edged Sword in Health and Disease
Kedzierski, R. M., & Yanagisawa, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.851 · Cited by 745
Lüscher, T. F., & Barton, M. (2000) · Circulation · doi:10.1161/01.cir.102.19.2434 · Cited by 596
Pulmonary Hypertension Due to Left Heart Disease
Guazzi, M., & Borlaug, B. A. (2012) · Circulation · doi:10.1161/circulationaha.111.085761 · Cited by 483
Effects of obstructive sleep apnea on endothelin-1 and blood pressure
Phillips, B. G., Narkiewicz, K., Pesek, C. A., Haynes, W. G., Dyken, M. E., & Somers, V. K. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917010-00010 · Cited by 464
Congestive Heart Failure: Fifty Years of Progress
Braunwald, E., & Bristow, M. R. (2000) · Circulation · doi:10.1161/01.cir.102.suppl_4.iv-14 · Cited by 437
The right ventricle in pulmonary hypertension
Chin, K. M., Kim, N. H. S., & Rubin, L. J. (2005) · Coronary Artery Disease · doi:10.1097/00019501-200502000-00003 · Cited by 429
Moraes, D. L., Colucci, W. S., & Givertz, M. M. (2000) · Circulation · doi:10.1161/01.cir.102.14.1718 · Cited by 401
Endothelin as a regulator of cardiovascular function in health and disease
Haynes, W. G., & Webb, D. J. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816080-00001 · Cited by 360
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., Weller, T., Bolli, M. H., Boss, C., Buchmann, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142976 · Cited by 329
Bonderman, D., Ghio, S., Felix, S. B., Ghofrani, H.-A., Michelakis, E., Mitrovic, V., Oudiz, R. J., Boateng, F., Scalise, A.-V., Roessig, L., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001458 · Cited by 326
Vascular endothelin in hypertension
Schiffrin, E. L. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.03.004 · Cited by 305
Mulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J. P., Lallemand, F., Renet, S., Lerebours, G., Mahlberg-Gaudin, F., & Thuillez, C. (2004) · Circulation · doi:10.1161/01.cir.0000118464.48959.1c · Cited by 294
Self-citationSütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O. (1998) · Circulation · doi:10.1161/01.cir.98.21.2262 · Cited by 287
Packer, M., McMurray, J., Massie, B. M., Caspi, A., Charlon, V., Cohen-Solal, A., Kiowski, W., Kostuk, W., Krum, H., Levine, B., et al. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.05.006 · Cited by 275
Borovac, J. A., D'Amario, D., Bozic, J., & Glavas, D. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i8.373 · Cited by 195
Metadata
- Authors
- Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J. P., Lallemand, F., Compagnon, P., Macé, B., Comoy, E., Letac, B., & Thuillez, C.
- Venue
- Circulation
- Published
- 1997-09-16
- Volume
- 96
- Issue
- 6
- Pages
- 1976-1982
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2050153745
- Cited by
- 360
- References
- 30
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.